HLB Pharma has surpassed 200 billion won in consolidated annual revenue for the first time since its founding.


On February 3, HLB Pharma announced through a disclosure titled "Change of 30% or More (15% or More for Large Corporations) in Sales or Profit Structure" that its consolidated revenue for last year was 205.6 billion won, up 50% from the previous year. Operating profit inched down from 1.4 billion won in the previous year to 1.0 billion won. On a separate (non-consolidated) basis, revenue also rose 12.7% year-on-year to 154.5 billion won, outpacing the average growth rate of domestic pharmaceutical companies.

HLB Pharma Posts 205.6 Billion Won in Revenue and 1.0 Billion Won in Operating Profit Last Year View original image

This means the company has doubled its revenue in just three years since first surpassing 100 billion won in sales in 2022, a performance that is being viewed as steep growth achieved in an ultra-short period. The result is particularly meaningful given that the company still managed to post a double-digit growth rate even though contract manufacturing sales were temporarily suspended after demolishing the Hangnam plant to build a new factory.


This steep performance growth was driven by the contribution of Shinhwa Advance, acquired in April last year, whose results have been reflected in the consolidated financial statements and led to top-line expansion. In addition, the Consumer Healthcare Division succeeded in turning around both revenue and profit within two years of its launch, which also played a key role in underpinning the company’s stable revenue base.


A stable revenue structure centered on flagship products, combined with a strategy of aggressively targeting the superfood market with some 30 new products, translated into tangible results. In addition, "Albumin Intensive Gold" surpassed 10 billion won in annual sales by successfully differentiating itself from competing products through a positioning strategy that fully foregrounded the company’s pharmaceutical image.



HLB Pharma CEO Park Jaehyung said, "Surpassing 200 billion won in consolidated revenue for the first time since our founding is a meaningful achievement that demonstrates the strengthening of competitiveness across our entire business structure," adding, "We will continue to pursue sustainable growth through balanced development not only across all business divisions but also among our subsidiaries."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing